Administration of an antibody to E-selectin in patients with septic shock

Critical Care Medicine
G FriedmanJ L Vincent

Abstract

To determine the safety and pharmacokinetics of a murine monoclonal antibody to E-selectin in patients with newly developed septic shock. Open-label, prospective, phase II pilot study with escalating doses of the antibody. Intensive care unit of a 900-bed university hospital. Nine patients who survived the first 24 hrs of septic shock. In addition to standard therapy, an intravenous bolus of a murine monoclonal antibody to E-selectin, CY1787, was given at doses of 0.1 mg/kg (n = 3), 0.33 mg/kg (n = 3), and 1.0 mg/kg (n = 3). CY1787 was well tolerated in all patients. Signs of shock resolved in all patients, and organ failure entirely reversed in eight patients. All patients survived the 28-day follow-up. Administration of CY1787 was associated with an early and brisk increase in PaO2/FIO2 ratio (p < .001), from 146 +/- 38 mm Hg (19.5 +/- 5.1 kPa) to 205 +/- 45 mm Hg (27.3 +/- 6.0 kPa) after 2 hrs, and 250 +/- 58 mm Hg (33.3 +/- 7.7 kPa) after 12 hrs. A dose-related effect of CY1787 was suggested by an earlier weaning from catecholamine therapy and a faster resolution of organ failure in the high-dose group. Development of antimouse antibodies was documented in eight patients. This pilot study indicates that this antibody to E-s...Continue Reading

References

Dec 1, 1992·Clinical Immunology and Immunopathology·I EngelbertsC J van der Linden
Mar 1, 1992·Scandinavian Journal of Immunology·J F LeeuwenbergW A Buurman
Aug 1, 1992·The Journal of Surgical Research·I EngelbertsW A Buurman
Apr 1, 1991·The Journal of Surgical Research·C J WalshH J Sugerman
Jun 1, 1989·Critical Care Medicine·J M DebetsC J van der Linden
Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Feb 1, 1993·The Journal of Clinical Investigation·M P Bevilacqua, R M Nelson
Dec 1, 1993·The American Review of Respiratory Disease·J M Pilewski, S M Albelda

❮ Previous
Next ❯

Citations

Dec 5, 2002·Burns : Journal of the International Society for Burn Injuries·Mahmut BasogluS Selcuk Atamanalp
May 26, 1999·Infectious Disease Clinics of North America·C Parent, P Q Eichacker
Jun 24, 1999·Cytokine & Growth Factor Reviews·A Meager
Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean-Louis VincentMarc-Jacques Dubois
Jan 10, 2002·Critical Care Medicine·Irvith M CarvajalMark A Perrella
May 18, 1999·Archives of Disease in Childhood·P B BainesC A Hart
Aug 1, 1997·American Journal of Respiratory and Critical Care Medicine·C J CummingsA A Fowler
Mar 29, 2003·Expert Opinion on Biological Therapy·Niels C Riedemann, Peter A Ward
Oct 6, 1997·Surgery·B S CainA H Harken
Aug 16, 2000·Baillière's Best Practice & Research. Clinical Haematology·S N FaustM Levin
Aug 25, 2001·Journal of Endotoxin Research·M J Dubois, J L Vincent
May 17, 2003·Nature Reviews. Drug Discovery·John C Marshall
Dec 17, 2017·Cell and Tissue Research·Braedon McDonald

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.